A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Tareq SalousNikhil A ShuklaSandra K AlthouseSusan M PerkinsMuhammad FurqanTiciana LealAnne M TraynorLawrence E FeldmanNasser H HannaGregory Durm

Published in: Cancer (2022)

Pembrolizumab plus next-line chemotherapy in patients with advanced NSCLC who experienced PD after a clinical benefit from a CPI was associated with statistically significant higher PFS in comparison with historical controls of single-agent chemotherapy alone.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
locally advanced
squamous cell carcinoma
small cell lung cancer
chemotherapy induced
big data
deep learning